文献速递艾滋病与性传播感染病毒性肝炎

HIV/HCV合并感染者的临床结局:HCV治疗的影响

Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment.
PubMed 文献 · Clin Infect Dis · 2020-01-01

基于EuroSIDA队列16 618名HIV感染者,按HCV RNA及治疗状态分组,比较终末期肝病(ESLD)、非艾滋病定义恶性肿瘤(NADM)和心血管疾病(CVD)发生率。调整后,NADM和CVD发生率在各组间无差异;与治愈组相比,HCV阴性者和自发清除者ESLD发生率降低,未治疗慢性HCV和治疗失败者ESLD发生率显著升高。

要点

  • HCV治愈与ESLD发生率显著降低相关,支持成功HCV治疗的重要性。
  • NADM和CVD发生率与HCV分组无关。
  • 未治疗慢性HCV或治疗失败者ESLD风险显著高于治愈者。

核心结论

  • NADM和CVD发生率与HCV分组无关,而HCV治愈者ESLD发生率显著低于未治疗或治疗失败者。

研究设计与样本

  • EuroSIDA队列研究,纳入2001年1月后已知HCV状态的HIV感染者16 618名,中位随访8.3年(IQR 3.1-13.7)。

主要发现

  • 随访期间共发生887例CVD、902例NADM和436例ESLD事件。
  • 粗发生率/1000人年:CVD 6.4(95%CI 6.0-6.9),NADM 6.5(95%CI 6.1-6.9),ESLD 3.1(95%CI 2.8-3.4)。
  • 调整后,NADM和CVD发生率在5组间无差异。
  • 与治愈组相比,HCV阴性者ESLD调整发生率比aIRR 0.22(95%CI 0.14-0.34),自发清除者aIRR 0.61(95%CI 0.36-1.02)。
  • 与治愈组相比,未治疗慢性HCV者ESLD aIRR 1.47(95%CI 1.02-2.13),治疗失败者aIRR 1.80(95%CI 1.22-2.66)。

临床怎么用

  • 对HIV/HCV合并感染者,应积极追求HCV治愈以降低ESLD风险。
  • HCV治疗失败或未治疗者需加强ESLD监测与管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarkers, but its impact on clinical endpoints among treated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear. METHODS: People living with HIV from EuroSIDA with a known HCV status after January 2001 were classified into strata based on time-updated HCV RNA measurements and HCV treatment, as either HCV antibody-negative; spontaneously resolved HCV; chronic, untreated HCV; cured HCV (HCV RNA-negative); or HCV treatment failures (HCV RNA-positive). Poisson regression was used to compare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular carcinoma [HCC]), non-acquired immunodeficiency virus defining malignancy (NADM; excluding HCC), and cardiovascular disease (CVD). RESULTS: There were 16 618 persons included (median follow-up 8.3 years, interquartile range 3.1-13.7). There were 887 CVD, 902 NADM, and 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval [CI] 6.0-6.9) for CVD, 6.5 (95% CI 6.1-6.9) for NADM, and 3.1 (95% CI 2.8-3.4) for ESLD. After adjustment, there were no differences in incidence rates of NADM or CVD across the 5 groups. HCV-negative individuals (adjusted incidence rate ratio [aIRR] 0.22, 95% CI 0.14-0.34) and those with spontaneous clearance (aIRR 0.61, 95% CI 0.36-1.02) had reduced rates of ESLD compared to cured individuals. Persons with chronic, untreated HCV infections (aIRR 1.47, 95% CI 1.02-2.13) or treatment failure (aIRR 1.80, 95% CI 1.22-2.66) had significantly raised rates of ESLD, compared to those who were cured. CONCLUSIONS: Incidences of NADM or CVD were independent of HCV group, whereas those cured had substantially lower incidences of ESLD, underlining the importance of successful HCV treatment for reducing ESLD.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mocroft A, Lundgren J, Gerstoft J, et al. Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment. Clin Infect Dis. 2020. PMID: 31504296. doi:10.1093/cid/ciz601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。